Lin Yu-Hsin, Chief Executive Officer and Director of Belite Bio, Inc, filed a Form 4 on August 14, 2026, disclosing the sale of 365 American depositary shares on August 12, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Lin Yu-Hsin, Chief Executive Officer and Director of Belite Bio, Inc (NASDAQ:BLTE)
  • First transaction: 142 American depositary shares disposed of at $180.00 per share on August 12, 2026
  • Second transaction: 223 American depositary shares disposed of at $180.57 per share on August 12, 2026
  • Total shares sold: 365 American depositary shares across both transactions
  • Remaining ownership: 170,569 American depositary shares held directly following the reported transactions
  • Trading plan: Sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025
  • Share structure: Each American depositary share represents one ordinary share, par value US$0.0001, of the issuer

Belite Bio CEO Lin Yu-Hsin Discloses Two ADS Sales Under 10b5-1 Plan

According to the filing, Lin Yu-Hsin, who serves as both Chief Executive Officer and Director of Belite Bio, Inc, conducted two separate dispositions of American depositary shares on August 12, 2026. The first transaction involved 142 shares sold at $180.00 per share, reducing direct beneficial ownership to 170,792 shares. The second transaction involved 223 shares sold at $180.57 per share, bringing direct beneficial ownership to 170,569 shares.

The filing discloses that both sales "were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025." The filing also notes that the Form 4 checkbox for Rule 10b5-1(c) compliance is checked, indicating the transactions are intended to satisfy the affirmative defense conditions of that rule. All shares are reported as directly owned.

The filing was signed by Lin Yu-Hsin and submitted on August 14, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

Lin Yu-Hsin, CEO and Director of Belite Bio, Inc (NASDAQ:BLTE), disclosed the sale of 365 American depositary shares on August 12, 2026, at prices of $180.00 and $180.57 per share, under a Rule 10b5-1 plan adopted December 23, 2025. Remaining direct ownership stands at 170,569 shares.